Diagonal Therapeutics Reports First Patient Dosed in P-I/II (DIAMOND) Trial of DIAG723 for HHT

Shots: Diagonal has dosed the first patient with DIAG723, a clustering agonist antibody, in P-I/II (DIAMOND) trial (n=~93) for people living with hereditary hemorrhagic telangiectasia (HHT) Trial will evaluate DIAG723 (SC) vs PBO in 3 parts: Part A (P-I) will assess single ascending doses; Part B (P-II) will evaluate multiple doses over 14wks. for safety & preliminary efficacy, incl. nosebleed frequency/severity & hematological parameters Part C (P-II) will evaluate multiple doses of DIAG723 in HHT pts with coexisting pulmonary arterial hypertension, assessing safety and exploratory effects on HHT and pulmonary-related measures Ref: Globenewswire   |   Image: Diagonal Therapeutics   |  Press Release R PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com The post Diagonal Therapeutics Reports First Patient Dosed in P-I/II (DIAMOND) Trial of DIAG723 for HHT appeared first on PharmaShots.